CRSP CRISPR Therapeutics 添加自选 39.690 -1.600-3.88% 收盘价 01/10 16:00 (美东) 39.720 +0.030+0.08% 盘后20:01 (美东) 33.88亿总市值-14.23市盈率TTM 40.370最高价38.510最低价240.85万股成交量40.040今开41.290昨收9483.52万成交额2.87%换手率亏损市盈率(静)8535.35万总股本91.10052周最高1.75市净率33.31...
美股市场个股详情 CRSP CRISPR Therapeutics 添加自选 43.833 -0.398-0.90% 交易中 01/24 14:49 (美东) 37.41亿总市值-15.71市盈率TTM 45.100最高价43.000最低价165.35万股成交量44.580今开44.230昨收7284.23万成交额1.97%换手率亏损市盈率(静)8535.35万总股本91.10052周最高1.93市净率36.79亿流通值36.52052周最低--...
🎊 55% Off New Year's Sale!* 🎊 Begin 2025 with a commitment to your financial well-being. Take advantage of our new member offer. Since inception,Motley Fool Stock Advisorhas historically beaten the S&P 500 bymore than717.68%!** New members can get a55% discount*ANDStock Advisor’sto...
Stay up to date with the latest CRISPR Therapeutics AG stock price movements on Seeking Alpha's interactive chart. View comprehensive price data and historical prices on CRSP here.
CRISPR Therapeutics( CRSP ) Search: Valuation Name Last Updated Buy Or Fear CRISPR Therapeutics (CRSP) Stock? 2023-11-24 CRISPR Therapeutics (CRSP) Valuation: CRSP Stock Looks Slightly Expensive With $39 Price Estimate 2021-07-16 . Financials ...
Stock Price41.02 Revenue$0000 View About CRISPR Therapeutics CRISPR Therapeutics (CRSP) operates as a gene editing company. The company develops gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform, which allows for changes to genomic deoxyribonucleic acid (DNA). Its th...
Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $64.00, a 29.7% upside from current levels. In a report released today, Barclays also maintained a Hold rating on the stock with a $55.00 pric...
在富途牛牛的免费在线期权交易平台上查找CRISPR Therapeutics (CRSP)的期权链,包括行权价格、到期日和成交量数据。
The U.K.’s conditional marketing authorization for Vertex Pharmaceuticals and CRISPR Therapeutics’ gene-edited therapy exa-cel raises some potential safety concerns with the risk of off-target effects.
Yet, all is not lost.Three of the leading companies in CRISPR human therapy — Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), and Intellia Therapeutics (NTLA) — are exploringvarious strategiesto get their therapies past the immune system.One solution being considered is to edit the cell ...